Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-25T17:22:54.347Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers

Published online by Cambridge University Press:  22 May 2020

Hélène Verdoux Open the ORCID record for Hélène Verdoux [Opens in a new window] ,
Clélia Quiles ,
Laura Bon ,
Isabelle Chéreau-Boudet ,
Julien Dubreucq ,
Lucia Fiegi ,
Nathalie Guillard-Bouhet ,
Catherine Massoubre ,
Julien Plasse  and
Nicolas Franck
Hélène Verdoux*
Affiliation:
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000Bordeaux, France Centre Référent de Réhabilitation Psychosociale (C2RP), Centre Hospitalier Charles Perrens, F-33000Bordeaux, France
Clélia Quiles
Affiliation:
Centre Référent de Réhabilitation Psychosociale (C2RP), Centre Hospitalier Charles Perrens, F-33000Bordeaux, France
Laura Bon
Affiliation:
Centre Ressource de Réhabilitation Psychosociale et de Remédiation Cognitive (CRR), Hôpital Le Vinatier, Centre National de la Recherche Scientifique (CNRS) et Université de Lyon, Lyon, France
Isabelle Chéreau-Boudet
Affiliation:
Centre Référent Conjoint de Réhabilitation (CRCR), Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
Julien Dubreucq
Affiliation:
Centre Référent de Réhabilitation Psychosociale et de Remédiation Cognitive (C3R), Centre Hospitalier Alpes Isère/Réseau Handicap Psychique, St Martin d'Hères; ReHPSY, Centre Hospitalier Alpes Isère, Grenoble, France
Lucia Fiegi
Affiliation:
CREATIV & URC Pierre Deniker, Centre Hospitalier Laborit, Poitiers, France
Nathalie Guillard-Bouhet
Affiliation:
Centre Référent de Réhabilitation Psychosociale de Limoges (C2RL), Limoges, France
Catherine Massoubre
Affiliation:
REHALise, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
Julien Plasse
Affiliation:
Centre Ressource de Réhabilitation Psychosociale et de Remédiation Cognitive (CRR), Hôpital Le Vinatier, Centre National de la Recherche Scientifique (CNRS) et Université de Lyon, Lyon, France
Nicolas Franck
Affiliation:
Centre Ressource de Réhabilitation Psychosociale et de Remédiation Cognitive (CRR), Hôpital Le Vinatier, Centre National de la Recherche Scientifique (CNRS) et Université de Lyon, Lyon, France Centre Référent Lyonnais de Réhabilitation Psychosociale (CL3R), Centre Hospitalier Le Vinatier, Lyon, France
*
Author for correspondence: Hélène Verdoux, E-mail: helene.verdoux@u-bordeaux.fr
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Few studies have explored whether high-anticholinergic load may hamper rehabilitation in persons with schizophrenia. We aim to explore the associations between anticholinergic load of psychotropic treatment and functioning or cognitive performances of persons with psychosis engaged in psychosocial rehabilitation.

Methods

The study was performed using data collected at baseline assessment in the REHABase cohort including persons referred to a French network of psychosocial rehabilitation centers. The composite-rating scale developed by Salahudeen et al. was used to rate the anticholinergic load of psychotropic drugs prescribed at baseline assessment. The associations between total anticholinergic load score (categorized as ‘low’ <3 v. ‘high’ ⩾3) and functioning or cognitive characteristics were explored using multivariate analyses.

Results

Of the 1012 participants with schizophrenia spectrum disorders identified in the REHABase, half used at least two psychotropic drugs with anticholinergic activity and one out of three was prescribed at least one psychotropic drug with high-anticholinergic activity. High-anticholinergic load was significantly associated with lower stage of recovery [odds ratio (OR) = 1.70, 95% confidence interval (CI) 1.05–2.76, p = 0.03], poor mental well-being (OR = 1.55, 95% CI 1.02–2.33, p = 0.04) and poor self-rated medication adherence (OR = 2.14, 95% CI 1.29–3.53, p = 0.003). Regarding cognition, a high-anticholinergic score was associated with poorer delayed-episodic memory (OR = 1.69, 95% CI 1.01–2.85, p = 0.05) and at the trend level with faster completion time on the test exploring executive performance (OR = 0.67, 95% CI 0.43–1.04, p = 0.07).

Conclusions

The psychosocial rehabilitation plan of persons with psychosis should integrate optimization of psychotropic treatment in order to lessen the functional and cognitive impact of high-anticholinergic load.

Keywords

Anticholinergiccognitionfunctional outcomepsychosocial rehabilitationquality of life
Type
Original Article
Information
Psychological Medicine , Volume 51 , Issue 16 , December 2021 , pp. 2789 - 2797
Check for updates
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4th ed., Text Revision (DSM-IV-TR)). Washington, DC, USA: American Psychiatric Association.Google Scholar
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Association.Google Scholar
Ancelin, M. L., Artero, S., Portet, F., Dupuy, A. M., Touchon, J., & Ritchie, K. (2006). Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ, 332, 455–459.CrossRefGoogle ScholarPubMed
Andresen, R., Caputi, P., & Oades, L. (2006). Stages of recovery instrument: Development of a measure of recovery from serious mental illness. Australian New Zealand Journal of Psychiatry, 40, 972–980.CrossRefGoogle ScholarPubMed
Ang, M. S., Abdul Rashid, N. A., Lam, M., Rapisarda, A., Kraus, M., Keefe, R. S. E., & Lee, J. (2017). The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. Journal of Clinical Psychopharmacology, 37, 651–656.CrossRefGoogle ScholarPubMed
Ballesteros, A., Sanchez-Torres, A. M., Lopez-Ilundain, J. M., Cabrera, B., Lobo, A., Gonzalez-Pinto, A. M., … Group, P. E. (2018). Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? Psychological Medicine, 48, 2247–2256.CrossRefGoogle ScholarPubMed
Bebbington, P. E., Angermeyer, M., Azorin, J. M., Marwaha, S., Marteau, F., & Toumi, M. (2009). Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatrica Scandinavica Supplementum, 118, 22–28.CrossRefGoogle Scholar
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., … Begaud, B. (2014). Benzodiazepine use and risk of Alzheimer's disease: Case-control study. BMJ, 349, g5205.CrossRefGoogle ScholarPubMed
Boyer, L., Simeoni, M. C., Loundou, A., D'Amato, T., Reine, G., Lancon, C., & Auquier, P. (2010). The development of the S-QoL 18: A shortened quality of life questionnaire for patients with schizophrenia. Schizophrenia Research, 121, 241–250.CrossRefGoogle ScholarPubMed
Brickenkamp, R., & Zillmer, E. (1998). The d2 test of attention. Seattle, WA: Hogrefe & Huber Publishers.Google Scholar
Campbell, N., Boustani, M., Limbil, T., Ott, C., Fox, C., Maidment, I., … Gulati, R. (2009). The cognitive impact of anticholinergics: A clinical review. Clinical Interventions in Aging, 4, 225–233.Google ScholarPubMed
Chakos, M. H., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., … Rosenheck, R. A. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services, 57, 1094–1101.CrossRefGoogle ScholarPubMed
Cicala, G., Barbieri, M. A., Spina, E., & de Leon, J. (2019). A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Expert Review of Clinical Pharmacology, 12, 219–234.CrossRefGoogle ScholarPubMed
Cohen, D. (2017). Clozapine and gastrointestinal hypomotility. CNS Drugs, 31, 1083–1091.CrossRefGoogle ScholarPubMed
Cossette, B., Bagna, M., Sene, M., Sirois, C., Lefebvre, G. P., Germain, O., … Payette, H. (2017). Association between anticholinergic drug Use and health-related quality of life in community-dwelling older adults. Drugs & Aging, 34, 785–792.CrossRefGoogle ScholarPubMed
Duran, C. E., Azermai, M., & Vander Stichele, R. H. (2013). Systematic review of anticholinergic risk scales in older adults. European Journal of Clinical Pharmacology, 69, 1485–1496.CrossRefGoogle ScholarPubMed
Eum, S., Hill, S. K., Rubin, L. H., Carnahan, R. M., Reilly, J. L., Ivleva, E. I., … Bishop, J. R. (2017). Cognitive burden of anticholinergic medications in psychotic disorders. Schizophrenia Research, 190, 129–135.CrossRefGoogle ScholarPubMed
Fournier, N., Demazieres-Pelletier, Y., Favier, S., Lemoine, L., & Gros, C. (2015). Test de commissions révisé. GREMOIRE 2. Tests et échelles des Maladies neurologiques avec symptomatologie cognitive. Paris: De Boeck Solal.Google Scholar
Franck, N., Bon, L., Dekerle, M., Plasse, J., Massoubre, C., Pommier, R., … Dubreucq, J. (2019). Satisfaction and needs in serious mental illness and autism spectrum disorder: The REHABase psychosocial rehabilitation project. Psychiatry Services, 70, 316–323.CrossRefGoogle ScholarPubMed
Garcia, S., Martinez-Cengotitabengoa, M., Lopez-Zurbano, S., Zorrilla, I., Lopez, P., Vieta, E., & Gonzalez-Pinto, A. (2016). Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. Journal of Clinical Psychopharmacology, 36, 355–371.CrossRefGoogle ScholarPubMed
Green, M. F. (2016). Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. Journal of Clinical Psychiatry, 77(Suppl 2), 8–11.CrossRefGoogle ScholarPubMed
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the “right stuff”? Schizophrenia Bulletin, 26, 119–136.CrossRefGoogle ScholarPubMed
Grober, E., Buschke, H., Crystal, H., Bang, S., & Dresner, R. (1988). Screening for dementia by memory testing. Neurology, 38, 900–903.CrossRefGoogle ScholarPubMed
Guy, W. (1976). ECDEU Assessment manual for psychopharmacology. Rockville, MD, U.S.: Department of Health, Education, and Welfare.Google Scholar
Hellewell, J. S. E. (2002). Patients' subjective experiences of antipsychotics: Clinical relevance. CNS Drugs, 16, 457–471.CrossRefGoogle ScholarPubMed
Hodge, K., & Jespersen, S. (2008). Side-effects and treatment with clozapine: A comparison between the views of consumers and their clinicians. International Journal of Mental Health Nursing, 17, 2–8.CrossRefGoogle ScholarPubMed
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., … Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet (London, England), 394, 939–951.CrossRefGoogle ScholarPubMed
Jaaskelainen, E., Juola, P., Hirvonen, N., McGrath, J. J., Saha, S., Isohanni, M., … Miettunen, J. (2013). A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin, 39, 1296–1306.CrossRefGoogle Scholar
Joshi, Y. B., Thomas, M. L., Hochberger, W. C., Bismark, A. W., Treichler, E. B. H., Molina, J., … Light, G. A. (2019). Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients. Schizophrenia Research, 208, 384–389.CrossRefGoogle ScholarPubMed
Lupu, A. M., Clinebell, K., Gannon, J. M., Ellison, J. C., & Chengappa, K. N. R. (2017). Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. Journal of Clinical Psychiatry, 78, e1270–e1275.CrossRefGoogle ScholarPubMed
Lysaker, P. H., Hamm, J. A., Hasson-Ohayon, I., Pattison, M. L., & Leonhardt, B. L. (2018). Promoting recovery from severe mental illness: Implications from research on metacognition and metacognitive reflection and insight therapy. World Journal of Psychiatry, 8, 1–11.CrossRefGoogle ScholarPubMed
Martin, R. (1972). Le test des commissions. Epreuve d'adaptation méthodique (2nd ed.). Bruxelles: Editest.Google Scholar
McGurk, S. R., Green, M. F., Wirshing, W. C., Wirshing, D. A., Marder, S. R., Mintz, J., & Kern, R. (2004). Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophrenia Research, 68, 225–233.CrossRefGoogle Scholar
Minzenberg, M. J., Poole, J. H., Benton, C., & Vinogradov, S. (2004). Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. American Journal of Psychiatry, 161, 116–124.CrossRefGoogle Scholar
Misdrahi, D., Verdoux, H., Llorca, P. M., & Bayle, F. J. (2004). Therapeutic adherence and schizophrenia: The interest of the validation of the French translation of Medication Adherence Rating Scale (MARS). L'Encephale, 30, 409–410.Google Scholar
Montastruc, F., Benevent, J., Touafchia, A., Chebane, L., Araujo, M., Guitton-Bondon, E., … Montastruc, J. L. (2018). Atropinic (anticholinergic) burden in antipsychotic-treated patients. Fundamental Clinical Pharmacology, 32, 114–119.CrossRefGoogle ScholarPubMed
Nielsen, J., Munk-Jorgensen, P., Skadhede, S., & Correll, C. U. (2011). Determinants of poor dental care in patients with schizophrenia: A historical, prospective database study. Journal of Clinical Psychiatry, 72, 140–143.CrossRefGoogle ScholarPubMed
Ogino, S., Miyamoto, S., Miyake, N., & Yamaguchi, N. (2014). Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry Clinical Neurosciences, 68, 37–49.CrossRefGoogle ScholarPubMed
Ogino, S., Miyamoto, S., Tenjin, T., Kitajima, R., Ojima, K., Miyake, N., … Yamaguchi, N. (2011). Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Progress Neuropsychopharmacology Biological Psychiatry, 35, 78–83.CrossRefGoogle Scholar
O'Reilly, K., O'Connell, P., Donohoe, G., Coyle, C., O'Sullivan, D., Azvee, Z., … Kennedy, H. G. (2016). Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: A 3-year prospective cohort study. Psychological Medicine, 46, 3199–3211.CrossRefGoogle ScholarPubMed
Pristed, S. G., Correll, C. U., & Nielsen, J. (2017). Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. Psychiatry Research, 255, 198–203.CrossRefGoogle ScholarPubMed
Prouteau, A., Verdoux, H., Briand, C., Lesage, A., Lalonde, P., Nicole, L., … Stip, E. (2005). Cognitive predictors of psychosocial functioning outcome in schizophrenia: A follow-up study of subjects participating in a rehabilitation program. Schizophrenia Research, 77, 343–353.CrossRefGoogle Scholar
Rudolph, J. L., Salow, M. J., Angelini, M. C., & McGlinchey, R. E. (2008). The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of Internal Medicine, 168, 508–513.CrossRefGoogle ScholarPubMed
Salahudeen, M. S., Duffull, S. B., & Nishtala, P. S. (2015). Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatrics, 15, 31.CrossRefGoogle ScholarPubMed
Strauss, M. E., Reynolds, K. S., Jayaram, G., & Tune, L. E. (1990). Effects of anticholinergic medication on memory in schizophrenia. Schizophrenia Research, 3, 127–129.CrossRefGoogle Scholar
Su, Y. A., Yan, F., Li, Q., Xiang, Y. T., Shu, L., Yu, X., … Si, T. M. (2017). Anticholinergic use trends in 14 013 patients with schizophrenia from three national surveys on the use of psychotropic medications in China (2002–2012). Psychiatry Research, 257, 132–136.CrossRefGoogle Scholar
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., … Stewart-Brown, S. (2007). The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): Development and UK validation. Health Quality of Life Outcomes, 5, 63.CrossRefGoogle ScholarPubMed
Thompson, K., Kulkarni, J., & Sergejew, A. A. (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia Research, 42, 241–247.CrossRefGoogle ScholarPubMed
Trousselard, M., Steiler, D., Dutheil, F., Claverie, D., Canini, F., Fenouillet, F., … Franck, N. (2016). Validation of the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) in French psychiatric and general populations. Psychiatry Research, 245, 282–290.CrossRefGoogle ScholarPubMed
Van der Linden, M. (2004). L'évaluation des troubles de la mémoire: Présentation de quatre tests de mémoire épisodique (avec leur étalonage). Marseille: Solal ed.Google Scholar
Verdoux, H., Quiles, C., Cervello, S., Dubreucq, J., Bon, L., Massoubre, C., … Franck, N. (2019). Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: A REHABase cohort study. Psychiatry Research, 281, 112543.CrossRefGoogle ScholarPubMed
Vinogradov, S., Fisher, M., Warm, H., Holland, C., Kirshner, M. A., & Pollock, B. G. (2009). The cognitive cost of anticholinergic burden: Decreased response to cognitive training in schizophrenia. American Journal of Psychiatry, 166, 1055–1062.CrossRefGoogle Scholar
Wechsler, D. (1997). Wechsler adult intelligence scale (3rd ed.). New York: Psychological Corporation.Google Scholar
Supplementary material: File

Verdoux et al. supplementary material

Table S1

Download Verdoux et al. supplementary material(File)
File 39.5 KB